NO20051585L - Stabilized exendin-4 compounds - Google Patents

Stabilized exendin-4 compounds

Info

Publication number: NO20051585L
Authority: NO; Norway
Prior art keywords: exendin; compounds; stabilized; stabilized exendin; molecule
Prior art date: 2002-10-02

Application number

NO20051585A

Other languages

English (en)

Norwegian (no)

Inventor

Kirsten Ebbehoj

Bjarne Due Larsen

Trine Jepsen

Carsten Boye Knudsen

David Knott

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-02

Filing date

2005-03-29

Publication date

2005-06-20

2005-03-29 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2005-06-20 Publication of NO20051585L publication Critical patent/NO20051585L/no

Links

JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 title abstract 3
108010011459 Exenatide Proteins 0.000 abstract 2
125000000539 amino acid group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229960001519 exenatide Drugs 0.000 abstract 2
239000000556 agonist Substances 0.000 abstract 1
239000007795 chemical reaction product Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20051585A 2002-10-02 2005-03-29 Stabilized exendin-4 compounds NO20051585L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41562602P	2002-10-02	2002-10-02
PCT/DK2003/000651 WO2004035623A2 (en)	2002-10-02	2003-10-02	Stabilized exendin-4 compounds

Publications (1)

Publication Number	Publication Date
NO20051585L true NO20051585L (no)	2005-06-20

Family

ID=32107880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051585A NO20051585L (no)	2002-10-02	2005-03-29	Stabilized exendin-4 compounds

Country Status (13)

Country	Link
US (2)	US7544657B2 (pl)
EP (1)	EP1546200A2 (pl)
JP (1)	JP2006517908A (pl)
KR (1)	KR20050083713A (pl)
AU (2)	AU2003268621B2 (pl)
BR (1)	BR0314996A (pl)
CA (1)	CA2500295A1 (pl)
MX (1)	MXPA05003335A (pl)
NO (1)	NO20051585L (pl)
PL (1)	PL377591A1 (pl)
RU (1)	RU2376314C2 (pl)
WO (1)	WO2004035623A2 (pl)
ZA (1)	ZA200502571B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
DK1603598T3 (da) *	2003-03-19	2009-01-26	Univ Bern	Radiomærkede konjugater baseret på substans P og anvendelser heraf
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
DE102004058306A1 (de) *	2004-12-01	2006-07-27	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
DE102005046113A1 (de)	2005-09-27	2007-03-29	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
BRPI0620586A2 (pt) *	2005-12-02	2011-11-16	Nastech Pharm Co	formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
JP2009520693A (ja) *	2005-12-08	2009-05-28	エムディーアールエヌエー，インコーポレイテッド	安定化されたエキセンディン製剤の粘膜送達
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
WO2008116294A1 (en) *	2007-03-23	2008-10-02	Matregen Corp.	Exendin analogs
JP2009019027A (ja) *	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
PL2229407T3 (pl) *	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
NZ586589A (en) *	2008-01-09	2012-04-27	Sanofi Aventis Deutschland	Novel insulin analogues having an extremely delayed time-action profile
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
EP2451471A1 (de) *	2009-07-06	2012-05-16	Sanofi-Aventis Deutschland GmbH	Langsamwirkende insulinzubereitungen
EP3202394A1 (de)	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Wässrige insulinzubereitungen enthaltend methionin
DE102010011919A1 (de)	2010-03-18	2011-09-22	Sanofi-Aventis Deutschland Gmbh	Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
PT2554183T (pt) *	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es) *	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
SG184988A1 (en)	2010-04-27	2012-11-29	Zealand Pharma As	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CN101891823B (zh) *	2010-06-11	2012-10-03	北京东方百泰生物科技有限公司	一种Exendin-4及其类似物融合蛋白
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EA201390450A1 (ru)	2010-09-28	2013-07-30	Амилин Фармасьютикалс, Ллк.	Полипептиды с увеличенной продолжительностью действия
CN102532301B (zh) *	2010-12-31	2014-09-03	上海医药工业研究院	一类新型的Exendin-4类似物及其制备方法
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP2014521594A (ja)	2011-05-25	2014-08-28	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	長持続期間デュアルホルモンコンジュゲート
WO2012160212A1 (en)	2011-05-25	2012-11-29	Camurus Ab	Peptide controlled-release formulations
CN104271588B (zh)	2011-07-08	2017-10-10	安米林药品有限责任公司	具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN102309453A (zh) *	2011-09-27	2012-01-11	四川大学	醋酸艾塞那肽多囊脂质体及其制备方法
SI2763690T1 (sl)	2011-10-04	2016-03-31	Sanofi-Aventis Deutschland Gmbh	Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke
EP2763691A1 (en)	2011-10-04	2014-08-13	Sanofi-Aventis Deutschland GmbH	Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
CA2853884A1 (en)	2011-11-03	2013-05-10	Zealand Pharma A/S	Glp-1 receptor agonist peptide gastrin conjugates
AR091422A1 (es) *	2012-06-14	2015-02-04	Sanofi Sa	Analogos peptidicos de la exendina 4
MY170671A (en)	2012-07-23	2019-08-26	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk) *	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
ES2624961T3 (es) *	2013-03-21	2017-07-18	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos de péptido que contienen imida cíclica
ES2623979T3 (es)	2013-03-21	2017-07-12	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos peptídicos que contienen hidantoína
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
SI3057984T1 (sl)	2013-10-17	2018-10-30	Zealand Pharma A/S	Acilirani glukagonski analogi
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
CN103613655B (zh) *	2013-11-20	2015-05-13	陕西东大生化科技有限责任公司	一种低成本纯化艾塞那肽的方法
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
RU2016132340A (ru)	2014-01-09	2018-02-14	Санофи	Стабилизированные фармацевтические составы на основе инсулина аспарта
CN105899191B (zh)	2014-01-09	2020-06-16	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
KR20160104724A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) *	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
TWI705973B (zh)	2014-10-29	2020-10-01	丹麥商西蘭製藥公司	Ｇｉｐ促效劑化合物及方法
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
TWI707867B (zh)	2015-04-16	2020-10-21	丹麥商西蘭製藥公司	醯化之昇糖素類似物
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3429608A4 (en)	2016-03-16	2019-12-11	Prolynx LLC	CONJUGATES WITH EXTENDED RELEASE OF EXENATID ANALOG
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018104561A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
BR112020020647A2 (pt)	2018-04-10	2021-02-23	Sanofi-Aventis Deutschland Gmbh	síntese de lixisenatida com capeamento
KR102793451B1 (ko) *	2018-04-10	2025-04-11	사노피-아벤티스 도이칠란트 게엠베하	고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법
TW202015735A (zh)	2018-05-30	2020-05-01	法商賽諾菲公司	包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
WO2020206358A1 (en)	2019-04-05	2020-10-08	Prolynx Llc	Improved conjugation linkers
JP7544838B2 (ja)	2020-03-06	2024-09-03	サノフイ	選択的ｇｉｐ受容体アゴニストとしてのペプチド
KR20230157443A (ko) *	2021-03-17	2023-11-16	더 트러스티즈 오브 프린스턴 유니버시티	펩티드 또는 폴리머에 결합된 키누레닌 및 기타 uv 흡수 산화 아미노산에서 유래된 자외선 차단제
CN115521368B (zh) *	2021-06-25	2024-08-23	江苏鸿永医药技术有限公司	毒蜥外泌肽-4衍生物
CA3230915A1 (en)	2021-09-06	2023-03-09	Thomas Boehme	New peptides as potent and selective gip receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
ES2084698T5 (es)	1989-05-04	2005-03-01	Southern Research Institute	Procedimiento de encapsulacion.
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US5846747A (en)	1992-03-25	1998-12-08	Novo Nordisk A/S	Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da)	1992-03-25	1992-03-25	Bernard Thorens	Peptid
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP2275089A1 (en)	1993-11-19	2011-01-19	Alkermes Controlled Therapeutics, Inc.	Preparation of biodegradable microparticles containing a biologically active agent
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
DE19637230A1 (de) *	1996-09-13	1998-03-19	Boehringer Mannheim Gmbh	Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
JP2000516912A (ja) *	1996-06-05	2000-12-19	ロシュダイアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
ES2359031T3 (es)	1996-08-08	2011-05-17	Amylin Pharmaceuticals, Inc.	Composición farmacéutica que comprende un péptido de exendina-4.
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4798814B2 (ja)	1997-01-07	2011-10-19	アミリン・ファーマシューティカルズ，インコーポレイテッド	食物摂取低減用のエキセンジンおよびそのアゴニストの使用
AU5850798A (en)	1997-02-05	1998-08-26	1149336 Ontario Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en)	1997-03-03	1998-12-08	1149336 Ontario Inc.	Method of using exendin and GLP-1 to affect the central nervous system
DK1019077T4 (da)	1997-08-08	2011-03-07	Amylin Pharmaceuticals Inc	Hidtil ukendte exendinagonistforbindelser
AU756836B2 (en)	1997-11-14	2003-01-23	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
WO1999025727A2 (en)	1997-11-14	1999-05-27	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
AU1617399A (en)	1997-12-05	1999-06-28	Eli Lilly And Company	Glp-1 formulations
ATE366115T1 (de)	1998-02-13	2007-07-15	Amylin Pharmaceuticals Inc	Inotropische und diuretische effekte von exendin und glp-1
AU3247799A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP4394279B2 (ja)	1998-03-09	2010-01-06	ジーランドファーマアクティーゼルスカブ	酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
ATE269103T1 (de)	1998-03-13	2004-07-15	Novo Nordisk As	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU6294899A (en)	1998-10-07	2000-04-26	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6271241B1 (en)	1999-04-02	2001-08-07	Neurogen Corporation	Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
CN1372570A (zh) *	1999-04-30	2002-10-02	安米林药品公司	修饰的exendin和exendin激动剂
EP1180121B9 (en)	1999-05-17	2004-09-08	Conjuchem, Inc.	Long lasting insulinotropic peptides
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels

2003
- 2003-10-02 PL PL377591A patent/PL377591A1/pl not_active Application Discontinuation
- 2003-10-02 RU RU2005113291/04A patent/RU2376314C2/ru not_active IP Right Cessation
- 2003-10-02 CA CA002500295A patent/CA2500295A1/en not_active Abandoned
- 2003-10-02 AU AU2003268621A patent/AU2003268621B2/en not_active Ceased
- 2003-10-02 JP JP2004543971A patent/JP2006517908A/ja not_active Ceased
- 2003-10-02 MX MXPA05003335A patent/MXPA05003335A/es active IP Right Grant
- 2003-10-02 BR BR0314996-0A patent/BR0314996A/pt not_active IP Right Cessation
- 2003-10-02 EP EP03747852A patent/EP1546200A2/en not_active Withdrawn
- 2003-10-02 KR KR1020057005716A patent/KR20050083713A/ko not_active Ceased
- 2003-10-02 WO PCT/DK2003/000651 patent/WO2004035623A2/en not_active Ceased
- 2003-10-02 US US10/529,858 patent/US7544657B2/en not_active Expired - Fee Related
2005
- 2005-03-29 NO NO20051585A patent/NO20051585L/no not_active Application Discontinuation
- 2005-03-30 ZA ZA200502571A patent/ZA200502571B/en unknown
2009
- 2009-04-15 AU AU2009201477A patent/AU2009201477A1/en not_active Abandoned
- 2009-05-04 US US12/435,295 patent/US20090208565A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1546200A2 (en)	2005-06-29
CA2500295A1 (en)	2004-04-29
AU2003268621B2 (en)	2009-01-15
PL377591A1 (pl)	2006-02-06
KR20050083713A (ko)	2005-08-26
AU2003268621A1 (en)	2004-05-04
RU2376314C2 (ru)	2009-12-20
RU2005113291A (ru)	2006-01-20
JP2006517908A (ja)	2006-08-03
US7544657B2 (en)	2009-06-09
WO2004035623A3 (en)	2004-06-03
US20090208565A1 (en)	2009-08-20
WO2004035623A2 (en)	2004-04-29
US20060194719A1 (en)	2006-08-31
AU2009201477A1 (en)	2009-05-07
BR0314996A (pt)	2005-08-09
ZA200502571B (en)	2006-02-22
MXPA05003335A (es)	2005-07-05

Legal Events

Date	Code	Title	Description
2012-06-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20051585L (no)	2005-06-20	Stabilized exendin-4 compounds
NO20081211L (no)	2008-05-08	Xantinderivater som selektive HM74A agonister
NO20052690D0 (no)	2005-06-06	Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
EP1784188A4 (en)	2009-06-24	CONDENSED TRIAZOLE DERIVATIVES AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
DE60330485D1 (de)	2010-01-21	Zur behandlung von diabetes
DE602004023932D1 (de)	2009-12-17	3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
JO2230B1 (en)	2004-10-07	Dipeptidase inhibitors containing a heterocyclic ring of beta-amino rings for treatment or prevention of diabetes
NO20076040L (no)	2008-01-28	Nye laktam-sammensetninger
WO2005011581A3 (en)	2005-04-28	Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE59712555D1 (de)	2006-04-06	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE60226723D1 (de)	2008-07-03	Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
ATE522226T1 (de)	2011-09-15	Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
DK0695301T3 (da)	1996-12-09	Indolderivater som 5-HT1-lignende agonister til anvendelse ved migræne
WO2004069162A3 (en)	2005-05-19	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004064778A3 (en)	2005-05-12	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004112701A3 (en)	2005-02-10	Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006039325A3 (en)	2007-01-04	Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
BR9813260A (pt)	2000-08-22	Composições de limpeza contendo variantes de protease substituìdas por multiplicação
NO20056010L (no)	2006-01-20	Biaryloksymetylaren-karboksylsyrer
DK1268498T3 (da)	2005-08-08	Kardioprotektive phosphater
NO20050932L (no)	2005-04-15	1-pyridin-4-yl-ureaderivater
MXPA05013059A (es)	2006-03-02	Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
BR9506488A (pt)	1997-10-07	Preparação anti-helmintica
DE60225143D1 (de)	2008-04-03	Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes